Mylan N.V. (NASDAQ:MYL) and development partner Biocon Ltd. (OTC:BCNQY) announce the U.S. commercial launch of Ogivri (trastuzumab-dkst), a biosimilar to Roche’s (OTCQX:RHHBY) Herceptin.
Mylan owns exclusive commercialization rights in the U.S., Canada, Japan, Australia, New Zealand, the EU and European Free Trade Association countries. Biocon has co-exclusive rights with Mylan in the rest of the world.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.